STOCK TITAN

TELA Bio, Inc. - TELA STOCK NEWS

Welcome to our dedicated page for TELA Bio news (Ticker: TELA), a resource for investors and traders seeking the latest updates and insights on TELA Bio stock.

TELA Bio, Inc. (NASDAQ: TELA) is a pioneering medical technology company based in Malvern, Pennsylvania, dedicated to transforming the field of soft tissue reconstruction. With a mission to provide advanced, cost-effective solutions, TELA Bio focuses on enhancing clinical outcomes by prioritizing the preservation and restoration of a patient's own anatomy.

The company offers two primary product lines: OviTex and OviTex PRS Reinforced Tissue Matrices. These products are designed to improve clinical outcomes and reduce costs in hernia repair, abdominal wall reconstruction, and plastic and reconstructive surgery. OviTex, a reinforced tissue matrix, leverages the body's natural healing response while minimizing long-term exposure to synthetic materials.

In recent developments, TELA Bio has launched LIQUIFIX, the first approved adhesive-based product for affixing mesh without penetrating patient tissue. This innovation underscores TELA Bio's commitment to providing surgeons with cutting-edge, economically viable solutions that align with modern clinical practices.

Financially, TELA Bio is experiencing significant growth. For the first quarter of 2024, the company reported a revenue increase of 39% year-over-year, reaching $16.6 million. This growth is attributed to a mature sales force, strategic product launches, and an expanding customer base. Despite operational losses, the company achieved a notable decrease in net loss, demonstrating improved financial management and operational efficiency.

Moreover, TELA Bio actively collaborates with leading surgeons to continuously innovate and address the unmet needs in soft tissue repair. The company's partnership with experts ensures that its products meet the highest standards of efficacy and safety.

For the latest updates, TELA Bio frequently hosts earnings conference calls and webcasts, providing valuable insights into its financial performance and strategic initiatives. Investors and stakeholders can access these resources via the investor section of the company's website.

In summary, TELA Bio, Inc. is a dynamic and forward-looking company poised to make significant advancements in medical technology. By combining innovation with practical solutions, TELA Bio aims to reinvigorate the soft tissue reconstruction market and provide substantial benefits to hospitals, surgeons, and patients alike.

Rhea-AI Summary
TELA Bio approves inducement grants of restricted stock units to newly-hired employees.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.61%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.28%
Tags
conferences
-
Rhea-AI Summary

TELA Bio, Inc. (NASDAQ: TELA), a leading medical technology company, has announced that it will release its first quarter 2023 financial results on May 11, 2023. The management will host a conference call at 4:30 p.m. ET to discuss these results and provide a corporate update. TELA Bio specializes in innovative soft-tissue reconstruction solutions, aiming to enhance clinical outcomes while preserving the patient's anatomy. Interested investors can register to listen to the call online, with options for a replay available post-event. The company emphasizes its commitment to advanced, economically effective solutions that leverage patients' natural healing responses.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.74%
Tags
Rhea-AI Summary

TELA Bio, Inc. announced the pricing of an underwritten public offering of 4,750,000 shares of its common stock at $9.50 per share, aiming for gross proceeds of $45.125 million. This offering will close on April 21, 2023, subject to customary closing conditions. Additionally, underwriters received a 30-day option for 712,500 additional shares. The funds will be utilized for general corporate purposes, including sales and marketing, research and development, and working capital. The offering is made under an effective shelf registration statement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.17%
Tags
-
Rhea-AI Summary

TELA Bio, Inc. has announced a public offering of its common stock, with underwriters given a 30-day option to purchase an additional 15% of the shares. The offering is subject to market conditions and may vary in size and terms. TELA intends to use the proceeds for general corporate purposes, including sales and marketing, research and development, and working capital. The offering will be conducted under a shelf registration statement effective since December 29, 2020. Jefferies, Piper Sandler, and Lake Street are joint book-running managers. This press release does not serve as an offer to sell or a solicitation for purchase of these securities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.17%
Tags
-
Rhea-AI Summary

TELA Bio, a commercial-stage medical technology company, has announced that its OviTex Reinforced Tissue Matrix will be featured in three case reports at the 2023 SAGES conference in Montreal from March 29 - April 1. These presentations will focus on the use of OviTex in robotic-assisted hernia repair, showcasing its distinctive design that facilitates minimally invasive procedures. The reports include complex cases such as robotic hernia repairs in immunosuppressed patients and the treatment of Spigelian hernias. TELA Bio aims to optimize surgical outcomes while reducing reliance on permanent synthetic materials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.75%
Tags
none
Rhea-AI Summary

TELA Bio (NASDAQ: TELA) has received 510(k) clearance from the FDA for its OviTex PRS Long-Term Resorbable product, designed to reinforce soft tissue in plastic and reconstructive surgery. This addition complements the existing OviTex PRS portfolio, enhancing its offerings with a fully resorbable polymer and bi-directional stretch. The company aims to optimize clinical outcomes while prioritizing patient anatomy preservation. CEO Antony Koblish emphasizes this product's role in expanding clinical utility and reflecting TELA's commitment to innovation in soft-tissue repair.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.42%
Tags
none
-
Rhea-AI Summary

TELA Bio, Inc. reported strong financial results for Q4 2022 and full year 2022, achieving revenue of $11.6 million in Q4 and $41.4 million for the full year, marking growth of 39% and 41% respectively year-over-year. The increases were driven by heightened demand for OviTex® and OviTex PRS products, with year-over-year growth of 26% and 92%. Despite operational losses of $10 million for Q4 and $44.3 million for the full year, TELA anticipates revenue growth of 45% to 57% in 2023, projecting revenue between $60 million and $65 million. A new dual-source agreement and product launches further support their optimistic outlook.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.91%
Tags
-
Rhea-AI Summary

TELA Bio (NASDAQ: TELA) announces positive findings from six studies demonstrating the effectiveness of OviTex Reinforced Tissue Matrix in hernia repair and abdominal wall reconstruction. Published in 2022, these studies encompass data from 280 patients, showcasing lower complication and recurrence rates compared to traditional mesh products. The research highlights OviTex as a superior alternative in various applications, aligning with the growing demand for safer surgical options. With over two million hernia repairs expected in the US and Europe this year, TELA aims to enhance patient outcomes through innovative soft-tissue solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.74%
Tags
Rhea-AI Summary

TELA Bio, Inc. (NASDAQ: TELA), a company focused on innovative soft-tissue reconstruction solutions, will report its fourth quarter and full year 2022 financial results on March 21, 2023. A conference call and webcast will follow at 4:30 p.m. ET to discuss these results and provide corporate updates. TELA Bio aims to optimize clinical outcomes by prioritizing the preservation of patients' anatomy, providing economically effective solutions while minimizing long-term exposure to synthetic materials. Investors and interested parties can register for the call in advance or access a replay on TELA's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.85%
Tags

FAQ

What is the current stock price of TELA Bio (TELA)?

The current stock price of TELA Bio (TELA) is $2.86 as of December 24, 2024.

What is the market cap of TELA Bio (TELA)?

The market cap of TELA Bio (TELA) is approximately 112.7M.

What does TELA Bio, Inc. specialize in?

TELA Bio, Inc. specializes in developing and marketing tissue reinforcement materials for soft tissue reconstruction, including hernia repair and plastic surgery.

What are the main products offered by TELA Bio?

TELA Bio's main products include OviTex and OviTex PRS Reinforced Tissue Matrices, designed to improve clinical outcomes in hernia repair and plastic surgery.

Where is TELA Bio, Inc. located?

TELA Bio, Inc. is headquartered in Malvern, Pennsylvania, United States.

How has TELA Bio performed financially recently?

In Q1 2024, TELA Bio reported a 39% increase in revenue year-over-year, reaching $16.6 million, and a reduced net loss compared to the same period in 2023.

What recent product has TELA Bio launched?

TELA Bio recently launched LIQUIFIX, an adhesive-based product for affixing mesh without penetrating patient tissue.

How can investors stay updated on TELA Bio's performance?

Investors can stay updated by accessing earnings conference calls and webcasts available on the investor section of TELA Bio's website.

What is OviTex?

OviTex is a reinforced tissue matrix developed by TELA Bio to improve clinical outcomes and reduce costs in hernia repair and abdominal wall reconstruction.

Which market needs does TELA Bio aim to address?

TELA Bio aims to address unmet needs in soft tissue repair, particularly in hernia repair, abdominal wall reconstruction, and plastic and reconstructive surgery.

Is TELA Bio publicly traded?

Yes, TELA Bio, Inc. is publicly traded on NASDAQ under the ticker symbol TELA.

Who can be contacted for investor relations at TELA Bio?

For investor relations, TELA Bio's contact is Louisa Smith, who can be reached at ir@telabio.com.

TELA Bio, Inc.

Nasdaq:TELA

TELA Rankings

TELA Stock Data

112.65M
33.31M
7.32%
51.7%
0.85%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
MALVERN